Bioavailability (BA) is the percentage of a drug (or its pro-drug form) which is absorbed into the general circulation. BA is calculated by comparing the blood concentration profile of test article given intravenously to that given orally or by another administration routes (i.e, transdermal, pulmonary, subcutaneous).
Bioequivalence (BE) studies are investigations that compares the pharmacokinetic profile of a generic drug to that of the innovator. If the two products are deemed bioequivalent, it implies for all intents and purposes they are the same.
KCAS has conducted numerous bioavailability investigations, most frequently in dosing form optimization.
We have validated methods for a wide range of pharmaceutical compounds that can support your BA/BE investigations. We also can assist when your focus is optimization of bioavailability of dosing form needing rapid results using with our integrated drug discovery.